Upregulation of PAX2 Promotes the Metastasis of Esophageal Cancer through

Introduction
Esophageal cancer ranks as the ninth most common malignancy and the sixth most common cause of cancer-related death, with elevated incidence and mortality rates in developing countries [1, 2] . Approximately one-half of newly diagnosed esophageal cancer cases occur in China each year, and esophageal squamous cell carcinoma (ESCC) constitutes more than 90% of esophageal cancer diagnoses. Despite the currently available methods of aggressive treatment for ESCC, the prognosis of this cancer remains poor because of late diagnosis and the rapid metastasis of cancer cells [3, 4] . The pathology of ESCC remains complex and largely unknown. Transcription factors are central to cancer initiation and progression, serving as "switches" that turn specific sets of genes on or off [5, 6] .
The paired box (PAX) transcription factor family is characterized by a highly conserved paired-box DNA-binding domain. At present, nine paired box genes (PAX1 to PAX9) are known to occur in human beings [7, 8] . The temporal and spatial expressions of PAX genes are tightly regulated during embryogenesis. PAX2 is primarily expressed in embryo and downregulated when the development is completed [8] . PAX2 is widely expressed during the development of both ductal and mesenchymal components of the urogenital system. Moreover, PAX2 plays a critical role in the formation of the isthmic organizer that controls midbrain and cerebellum development by activating En2, Brn1, Sef, Tapp1 and Ncrms [9] . PAX2 expression can only be detected in the medullary regions of the kidney, the transitional urothelium of the ureter and bladder wall and the epithelial lining of the fallopian tube in adults [10, 11] . Specific mutations in PAX2 genes lead to a range of developmental abnormalities in both human beings and mouse models [12, 13] .
In recent years, PAX2 has been found to be re-expressed in multiple cancers, including renal [14] [15] [16] , ovarian [17, 18] , endometrial [19] and breast cancers [20] . Furthermore, the expression of PAX2 plays versatile roles in cancer progression. PAX2 suppresses Caspase-2-induced apoptosis in the renal collecting duct, thus stimulating proliferation and self-renewal [11] . A recent study has shown that PAX2 induces expression of Cyclin D1 by activating AP-1 and promotes the proliferation of colon cancer cells [21] . PAX2 is hyper-expressed in human metastatic prostate cancer, and knockdown of PAX2 represses cell growth and invasion [22] . Therefore, PAX2 has emerged as a hallmark of malignant cells, suggesting that it might be a potential target for cancer therapy [23, 24] . However, the role of PAX2 in cancer development may vary depending on the underlying tissue-specific conditions; furthermore, the biological significance of PAX2 may vary between cancer cells.
The clinical relevance of PAX2 and its biological function in ESCC have remained unclear. In this study, we investigated the expression of PAX2 and its functional consequences in ESCC. We demonstrate that PAX2 expression is significantly overexpressed in ESCC tissues compared to expression levels in normal tissues. In addition, PAX2 promotes metastasis through interleukin-5 (IL-5) in ESCC TE-1 and Eca-109 cells.
Materials and Methods
Tissue samples
For immunohistochemistry, 120 ESCC samples and 52 matched, adjacent normal esophagus tissues were collected from 102 patients, as previously reported [25, 26] . Fifteen normal esophageal tissues were obtained from surgical resections of trauma patients. These tissues were obtained postoperatively between 2010-2012 from the Gastrointestinal Center, Jiangyin People's Hospital, Medical School of University of Southeast of China (Jiangyin, China). For real-time PCR analysis, another 60 human ESCC tissues were used, as previously reported [25] .
All patients gave signed, informed consent for their tissues to be used for scientific research. Ethical approval for the study was obtained from the Jiangyin People's Hospital. All diagnoses were based on pathological and/or cytological evidence; the histological features of the specimens were evaluated by two senior pathologists according to the classification criteria from the WHO [27] .
Immunohistochemistry (IHC)
Three-micrometer-thick tissue paraffin sections were deparaffinized and heat-treated with citrate buffer, pH 6.0, for 7 min as an epitope retrieval protocol. Endogenous peroxidase was blocked with 3% hydrogen peroxide for 15 min at room temperature, and non-specific-binding sites were blocked with 4% skimmed milk powder for 30 min. Sections were then incubated with the PAX2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h (dilution 1:200) and mixed with 2% skimmed milk powder to again reduce unspecific staining. Biotinylated secondary antibody was then added for 30 min. Avidinbiotin-peroxidase complex (Dako LSAB2 system, DAKO Co., Carpinteria, CA) was added, and the color was developed using 3-3'-diaminobenzidine. Counterstaining was performed with hematoxylin. All steps were performed at room temperature.
IHC scoring was based on both cytoplasmic and nucleic staining. The stained sections were scored using the following criteria as reported previously [25, 26] : negative (-), < 10% of the whole tissue mass stained; weakly positive (+ 1), 10-25% of the whole tissue mass stained; moderately positive (+ 2), 25-75% of the whole tissue mass stained; and strongly positive (+ 3), > 75% of the tissue showed positive.
Reverse transcriptase-PCR (RT-PCR) and real-time PCR analysis.
Total RNA from esophageal tissues was extracted with TRIzol (Invitrogen, Carlsbad, CA) and reversely transcribed to cDNA using an oligo(dT) 12 primer and Superscript II (Invitrogen). The mRNA levels of target genes and the internal standard glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were measured by RT-PCR or real-time PCR in triplicate on a Prism 7500 real-time PCR machine (Applied Biosystems, Foster City, CA). The specific primers for the genes are listed in Table 1 .
PAX2 overexpression and RNAi
The human PAX2 (GenBank accession no. ENST00000428433) coding region was amplified by PCR using a primer pair specific to PAX2. The amplified fragment was inserted into the pcDNA3.1 vector. The plasmid was then sequenced for confirmation. The siRNA targeting PAX2 and siRNA control (siRNA-NC) used in this study were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture and transfection
The human esophageal cancer cell lines, TE-1 and Eca-109, was maintained in DMEM supplemented with 10% FBS and antibiotics (Gibco, Grand Island, NY). Cells were grown in a 37°C incubator with 5% CO 2 . For transfection, cells were transfected by Lipofectamine 2000 (Invitrogen, Carlsbad, CA) with plasmids or siRNAs.
Cell viability assay
Cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Cells were plated in 96-well plates. The next day, the cells were transfected with plasmids or siRNAs according to the experimental design. The cells were then incubated with 20 µl MTT (5 mg/ml) for 4 h. After the medium was removed, 100 µl DMSO was added and the optical density (OD) at 490 nm was measured using a Microplate Reader (Bio-Rad, Hercules, CA). The viability index was calculated as experimental OD value/control OD value. Three independent experiments were performed in quadruplicate.
Focus formation
Cells transfected with the indicated vectors were plated at low density (1,000 cells per 6-cm plate), incubated for 10 days and fixed and stained with crystal violet. Foci and colonies containing more than 50 cells were counted using a microscope. In vitro migration assay Migration was assayed using a modified Boyden chamber (Corning-Costar, Cambridge, MA) that contained a polycarbonate transwell membrane filter (6.5 mm diameter, 8 μm pore size). The upper chamber was plated with 1×10 5 TE-1 or Eca-109 cells in serum-free DMEM. The lower chamber contained 600 μl medium from vector-or siRNA-transfected cells. After 5 h incubation at 37°C in 5% CO 2 , the filter was removed. Non-migrated cells on the upper surface of the filter were wiped off. Migrated cells that remained on the bottom surface were fixed with methanol, stained with Giemsa and counted under a microscope. To confirm the involvement of MMPs, 10 nM batimasta (obtained from Selleck Chemicals, Houston, TX) was used.
Western blot Cells were lysed in Lysis buffer (Promega, Madison, WI) and centrifuged at 4 °C for 10 min. The supernatant was collected and subjected for Western-blot. Cytosolic and nuclear protein was extracted using the cytosolic and nuclear protein extract kit (Beyotime, Nantong, China). Fifty micrograms of protein from each lysate were fractionated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA). After blocking with 5% nonfat milk in PBS-Tween-20 for 1 h at room temperature, the membranes were blotted with the appropriate PAX2 (Santa Cruz Biotechnology, Santa Cruz, CA), P21, MMP-2, MMP-9 or GAPDH primary antibody (All from Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:1000 dilution. Membranes were then incubated with appropriate secondary antibodies linked to horseradish peroxidase at a 1:2000 dilution for 1 h at room temperature. After TBST washes, the blot was incubated in the ECL detection kit (Amersham Bioscience, Freiburg, Germany).
Microarray analysis
Microarray-based mRNA expression profiling was performed using the Roche-NimbleGen (135K array) Array (Roche, WI). The microarrays contained approximately 45,033 assay probes corresponding to all of the annotated human mRNA sequences (NCBI HG18, Build 36). Total RNA labeling and hybridization were performed using standard conditions according to manufacturer instructions. Genes with a fold change of 5 or greater were subsequently subjected to pathway analysis using Ingenuity Pathway Analysis (Redwood City, CA).
Luciferase assays
Two luciferase reporters containing fragment of the PAX2 promoters (-1322 to +1 and −960 to +16, relative to the transcription start site, respectively) was constructed by Shanghai Biobuy Co. Ltd. (Shanghai, China). For the luciferase assay, the reporter vector with the PAX2 promoter was co-transfected with pRL-TK (Promega, Madison, WI) to correct the transfection efficiency. Luciferase activity was measured with the Dual-Luciferase Reporter Assay System (Promega). Promoter activities were expressed as the ratio of Firefly luciferase to Renilla luciferase activities.
Quantitative chromatin immunoprecipitation (ChIP)
Eca-109 cells were used for ChIP assays. We used the EZ ChIP Kit (Upstate, Biotechnology, Lake Placid, NY) and followed the manufacturer's instructions as reported previously [28] . Briefly, 5×10 6 cells were cross-linked with 1% formaldehyde and sonicated to approximately 500 bp fragments. ChIP was conducted with antibodies against PAX2 and IgG. Input control DNA or immunoprecipitated DNA was amplified in a 20 μl reaction volume consisting of 4 μl eluted DNA template and primers specific for IL-5 promoter: (forward) 5'-TCTCCCTGCTATACTGACATCG-3' and (reverse) 5'-TTCCCAGTAGTTGTCCCATACA-3'. Both the immunoprecipitated fragments and the inputs were amplified by RT-PCR or real-time PCR (the PCR product is 330 bp).
Statistical analysis
Data are expressed as the mean ± standard error of the mean (SEM) of at least three independent experiments. Standard error bars were included for all data points. The data were then analyzed using Student's t test when only two groups were present or assessed by one-way analysis of variance (ANOVA) when more than two groups were compared. Correlation analysis of the mRNA expression data was performed using the Pearson test. Statistical analysis was performed using SPSS software (Release 17.0, SPSS Inc.). Data were considered significant if P < 0.05.
Results
Expression of PAX2 is upregulated in esophageal cancer tissues
To test the hypothesis that normal and cancerous esophageal tissues express different subsets of the PAX2 gene, we measured PAX2 expression by immunohistochemistry.
Immunohistochemical staining was performed in 15 paraffin-embedded normal esophageal tissues and 120 ESCC tissues, 52 of which had corresponding adjacent tumor tissues. The histopathological features of the patients are summarized in Table 2 . An overall stronger staining for PAX2 was frequently observed in the ESCC tissues, whereas very weak staining of PAX2 was observed in the normal samples (Fig. 1A) . Moreover, PAX2 protein is located in both the nucleus (green arrows) and cytoplasm (red arrows) of esophageal cancer cells. To confirm the distribution of PAX2 in cultured cells, TE-1 cells were transfected with a 
PAX2-overexpressing vector (pcDNA.3.1-PAX2) or a control vector (pcDNA3.1). Result form
Western blot showed that PAX2 was present in the nucleic and cytoplasmic extract of PAX2-overexpression cells (Fig. 1B) .
The samples were further scored by a pathologist, as described in the Materials and Methods section. As shown in Fig. 1C , PAX2 expression in normal esophageal tissues was similar to that in adjacent tumor tissues; however, there were significant differences in the expression of PAX2 among tumor tissues and between tumor tissues and adjacent tumor tissues (P = 0.002 and P = 0.003, respectively; Fig. 1C ). These results indicated an increase in the expression of PAX2 in esophageal carcinoma, suggesting a characteristic of this malignancy.
Association of PAX2 expression with clinicopathological factors
We next examined the association between the clinicopathological features and the expression of PAX2 in ESCC. As shown in Table 1 , PAX2 expression correlated with an advanced tumor stage (P = 0.001). The expression of PAX2 was found to be significantly higher in Stage III-IV tumors than in Stage I-II tumors (1.353 ± 0.088 vs. 1.933 ± 0.133, P < 0.0001). The expression of PAX2 was also associated with lymph node metastasis (pN) (P = 0.019) and lymphatic invasion (P = 0.005). Other clinicopathological parameters, including age, gender and differentiation, were not related to PAX2 expression (Table 3) .
PAX2 suppressed esophageal cancer cell growth in vitro
To explore the role of PAX2 in esophageal cancer cell growth, cells were first transfected with a PAX2-overexpressing vector (pcDNA.3.1-PAX2) or a control vector (pcDNA3.1), and the resulting growth was measured by the MTT assay and colony formation. The results showed that increased PAX2 expression suppressed cell growth and proliferation, as evidenced by decreased cell viability and colony size in both TE-1 and Eca-109 cells (Fig. 2A, 2C , 2E and 2G). We further knocked down PAX2 expression using an siRNA. The downregulation of PAX2 promoted cell proliferation and colony formation (Fig. 2B, 2D, 2F and 2H) . Western blot analysis further showed that PAX2 expression correlated with P21 expression (Fig. 4A-4D) , which is reported to be a negative regulator of cell cycle progression [29, 30] . Taken together, these results indicate that PAX2 suppresses esophageal tumor growth in vitro. 
PAX2 promoted migration esophageal cancer cells
The effect of PAX2 on TE-1 cell migration was measured using migration chambers. Conditioned medium from pcDNA3.1-PAX2-transfected TE-1 cells induced a ~2-fold increase in TE-1 cell migration relative to conditioned medium from pcDNA3.1-transfected cells (Fig. 3A) . Conversely, conditioned medium from the siRNA targeting PAX2-transfected TE-1 cells significantly decreased the number of migrated cells compared to the number of control cells (Fig. 3B and 3C) . Consistent results were obtained from Eca-109 cells (Fig. 3D  to 3F ). Western blot analysis showed that overexpression of PAX2 increased the expression of the metastasis effectors MMP2 and MMP9 (Fig. 4A and 4C ), whereas knockdown of PAX2 decreased their expression (Fig. 4B and 4D ) in both TE-1 and Eca-109 cells. To confirm the involvement of MMPs, transwell assay using batimasta, a well-established MMPs inhibitor, was conducted, Results showed that batimasta abolished PAX2-induced cell invasion (Fig. 5) , indicating that MMPs is involved in promoting cell migration. Taken together, these results indicated the metastasis-promoting role of PAX2 in esophageal cancer cells.
mRNA microarray screening of PAX2-affected genes
To further analyze the underlying mechanisms responsible for PAX2-mediated metastasis, we screened gene expression between pcDNA3.1 and pcDNA3.1-PAX2-transfected TE-1 cells (Fig. 6A) . Twenty-four hours after the transfection, a total of 212 genes (80 upregulated and 132 downregulated genes) were identified with an expression differential of 5-fold or greater between the two conditions ( Fig. 6B and Table 4 ). The raw array measures are accessible through Gene Expression Omnibus (GEO) series accession number GSE64093. We then validated the results from microarray analysis by RT-PCR. As shown in Fig. 6C , compared with irradiated cells, several genes dysregulated in microarray data, such as CNTNAP5, IL-5 and THRB, were remarkably increased in PAX2 overexpression cells, whereas the expression of TRAF5 was decreased, which was consistent with the microarray results. As expected, PAX2 appeared to have modulated the TE-1 cells via complex mechanisms. Pathway analysis revealed that PAX2 affected multiple pathways, including Wnt-protein binding, RNA polymerase II transcription factor binding and cytokine activity (Fig. 6D and 6E) . HIF-2α. Because ESCC is one of the most aggressive cancers, to date, no effective measures are available to cure ESCC. The metastasis of lymphadenopathy is a major pathway for the spread of tumor cells, and lymphatic invasion is an important factor in the decision to pursue a therapeutic strategy and the evaluation of prognoses [35] . In this study, we found that PAX2 levels are correlated with tumor stage, pN and lymphatic invasion, indicating that PAX2 is involved in esophageal oncogenesis and tumor development and that PAX2 may be a predicator of malignant degree.
PAX2 overexpression exhibits oncogenic properties, such as anti-apoptosis, proliferation promotion and drug resistance in multiple cancers [36, 37] . The function of PAX2 in proliferation has proven to be controversial, depending on the genetic background of cells [18] . In this study, we found that PAX2 suppresses TE-1 and Eca-109 cells by upregulating P21. PAX2 has been reported to activate a variety of cell membrane proteins, and inhibition of PAX2-positive cells reduces cell motility and invasiveness in prostate, ovarian and bladder cancers [18, 22, 38] . Consistent with previous findings, we found that PAX2 overexpression resulted in markedly increased metastasis capacity in vitro and in vivo. Knockdown of PAX2 expression with a short hairpin RNA confirmed the role of PAX2 in the promotion of metastasis in ESCC cells, which supports the findings obtained by examining ESCC tissues that PAX2 expression is associated with pN and lymphatic invasion. The downstream target genes of PAX2 have gradually been identified, and GDNF has been reported to be a PAX2 target in medulloblastoma [36] . PAX2 can regulate metalloproteinase ADAM10 expression by driving melanoma metastasis [39] . In colon cancer cells, PAX2 upregulates Cyclin D1 mediated by AP-1 to promote cell proliferation [21] . To comprehensively understand the functional targets of PAX2 in esophageal cancer, we performed mRNA microarray-based screening analysis in TE-1 cells. Through this analysis, we found that PAX2 overexpression affected multiple genes that function in multiple pathways. The above-reported PAX2-regulated targets were not included in the PAX2 effected gene list, suggesting that PAX2 targets may be cancer-type-specific or conditional. Among PAX2-affected mRNAs, IL-5 has been shown to promote tumor metastasis in bladder cancer cells [31, 32] . IL-5 is reported to be involved in a number of immune responses, such as helminth infection and allergy, by regulating the production and function of B cells, eosinophils, and basophils [40, 41] . However, little is known about the role of IL-5 in cancer cells. In this study, we demonstrated that esophageal TE-1 and Eca-109 cells express IL-5 mRNA and secrete IL-5, which promotes cell metastasis via an autocrine pathway. Moreover, two PAX2-binding sites were identified in the IL-5 promoter, and PAX2 stimulated IL-5 expression and secretion in esophageal cancer cells. The expression of PAX2 mRNA significantly correlated with that of IL-5 in normal esophageal and ESCC tissues. Taken together, we demonstrated IL-5 as a novel direct target of PAX2 in esophageal carcinoma.
Conclusion
In summary, we found that the PAX2 expression was significantly increased in tumor tissues and that its expression correlated with the ESCC stage, lymph node metastasis and lymphatic invasion in human ESCC tissue specimens. Furthermore, PAX2 overexpression increased metastasis capacity in vitro via the transcriptional upregulation of IL-5. Taken together, we demonstrated the overexpression of PAX2 in esophageal carcinoma and identified IL-5 as PAX2's effector for metastasis. Thus, PAX2 may be a biomarker for ESCC phenotypes and represents a novel therapeutic target.
